Before looking at the financial values or the trading statistics of Valeant Pharmaceuticals International, Inc. They now have $14.94 price objective on the specialty pharmaceutical company's stock. Scotiabank's target price points to a potential downside of 14.77% from the company's current price.
Other analysts have also issued research reports about the stock. TD Securities dropped their price target on shares of Valeant Pharmaceuticals Intl to C$20.50 and set a "hold" rating on the stock in a research note on Wednesday, May 10th. Finally, Guggenheim reissued a buy rating and issued a $55.00 target price on shares of Valeant Pharmaceuticals Intl in a report on Tuesday, February 28th. Royal Bank of Canada restated a sector perform rating and set a $19.00 price target (up previously from $18.00) on shares of Valeant Pharmaceuticals Intl in a research report on Wednesday, May 10th. A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range.
The company's consensus rating on Reuter's scale remained unchanged from 4 to 4 during a month.
Valeant Pharmaceuticals Intl (NYSE:VRX) opened at 14.08 on Wednesday. (VRX) has a market capitalization of 4.96 Billion while its Major Index membership is at 0. Valeant Pharmaceuticals Intl has a 52-week low of $8.31 and a 52-week high of $32.74.
While looking at the Stock's Performance, Valeant Pharmaceuticals International, Inc. now shows a Weekly Performance of 16.85%, where Monthly Performance is 48.52%, Quarterly performance is -11.89%, 6 Months performance is -21.78% and yearly performance percentage is -47.95%. (VRX) is its Earnings per Share or EPS. The company had revenue of $2.11 billion for the quarter, compared to analysts' expectations of $2.17 billion.
Arctic Council presents united front as Finland takes over from US
FOREIGN MINISTER MARGOT WALLSTROM: Perhaps our planet would say, I've been your best friend since the Industrial Revolution. But the text did not recommit its members to meet the pledges made.
The company's net profit margin stands at 14.30% whereas its return on equity (ROE) is 15.40%. The company's revenue for the quarter was down 11.1% on a year-over-year basis. With 17.17 million avg volume, 3 days are for Valeant Pharmaceuticals Internat (NYSE:VRX)'s short sellers to cover VRX's short positions. If we move forward to year-to-date check then we concluded that it resulted performance is negative with move of -3.03%. Moreover, Prudential Public Ltd Company has 0% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 75,000 shares. If you are viewing this report on another website, it was stolen and republished in violation of USA and worldwide copyright laws. The original version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/05/15/btig-research-reaffirms-neutral-rating-for-valeant-pharmaceuticals-intl-inc-vrx.html. NL Industries, Inc. has 0 buy ratings, 0 holds and 0 sells even after the stock tumbled -0.47% from its high of $10.9 to a $501.49 million market value through last close. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Shares for $278,000 were bought by DE SCHUTTER RICHARD U on Thursday, May 11. The shares were bought at an average cost of $10.72 per share, for a total transaction of $257,280.00. Following the acquisition, the director now owns 70,572 shares in the company, valued at $980,950.80. The disclosure for this purchase can be found here. (HOG) stock; watched recent volatility movements, they can see that shares have been recorded at 2.03% for the week, and 1.83% for the last month.
Institutional investors have recently added to or reduced their stakes in the company.
Brokerage houses, on average, are recommending investors to hold Valeant Pharmaceuticals International, Inc. Company insiders own 16.37% of the company's stock. World Asset Management Inc boosted its position in shares of Valeant Pharmaceuticals Intl by 1.5% in the first quarter. Ls Advsrs Ltd Limited Liability Company has invested 0% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Acrospire Investment Management LLC now owns 13,200 shares of the specialty pharmaceutical company's stock worth $324,000 after buying an additional 9,900 shares during the last quarter.
The number of shares traded in the last trading session was 34.17 Million.
Currently, EPS of Valeant Pharmaceuticals International, Inc.